updates from a study evaluating astx727 venetoclax for patients with aml
Published 2 years ago • 163 plays • Length 4:20Download video MP4
Download video MP3
Similar videos
-
1:19
astx727 a molecularly-targeted agent as personalized maintenance therapy in patients with aml
-
1:03
10-day astx727 (decitabine/cedazuridine) with venetoclax in the treatment of r/r aml
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:46
phase ii trial in progress: astx727 ± venetoclax in newly diagnosed mds/mpn
-
1:34
single-center study evaluating the outcomes of patients with aml who relapsed after allosct
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
8:21
quazar aml-001: a new standard for aml maintenance therapy
-
4:03
a phase i/ii study evaluating quizartinib plus decitabine and venetoclax in flt3-mutated aml
-
3:52
venetoclax & aml
-
2:25
current and emerging immune therapies in al amyloidosis: updates on hbi0101 & bispecifics
-
1:43
updates from a phase ii study of bomedemstat for the treatment of essential thrombocythemia
-
2:38
session highlights: transforming aml treatment and building on new approaches
-
1:36
improve study update: safety and efficacy of venetoclax retreatment in r/r cll
-
5:31
the role of venetoclax in older patients with aml
-
0:52
imroz trial updates: isa-vrd versus vrd in patients with ndmm ineligible for transplant
-
5:36
venetoclax and azacitidine in mds patients
-
1:21
trends in allosct for good-risk aml: a longitudinal study
-
3:46
a phase ib/ii trial of sonrotoclax plus dexamethasone in patients with r/r mm harboring t(11;14)